Abstract Inhibitions and antagonists of L-type Ca 2+ channels are important to both research and therapeutics. Here, we report C-terminus mediated inhibition (CMI) for Ca V 1.3 that multiple motifs coordinate to tune down Ca 2+ current and Ca 2+ influx toward the lower limits determined by endstage CDI (Ca 2+ -dependent inactivation). Among IQ V (preIQ 3 -IQ domain), PCRD and DCRD (proximal or distal C-terminal regulatory domain), spatial closeness of any two modules, e.g., by constitutive fusion, facilitates the trio to form the complex, compete against calmodulin, and alter the gating. Acute CMI by rapamycin-inducible heterodimerization helps reconcile the concurrent activation/inactivation attenuations to ensure Ca 2+ influx is reduced, in that Ca 2+ current activated by depolarization is potently (~65%) inhibited at the peak (full activation), but not later on (endstage inactivation,~300 ms). Meanwhile, CMI provides a new paradigm to develop Ca V 1 inhibitors, the therapeutic potential of which is implied by computational modeling of Ca V 1.3 dysregulations related to Parkinson's disease.
Introduction
L-type Ca 2+ channels (LTCC or Ca V 1 channels) play pivotal roles in numerous physiological functions by mediating Ca 2+ influx and membrane excitability . Among four isoforms of Ca V 1.1-Ca V 1.4 in LTCC family, Ca V 1.3 channels exhibit unique biophysical properties (Lieb et al., 2014; Xu and Lipscombe, 2001 ) involving diverse regulatory mechanisms Christel and Lee, 2012; Huang et al., 2012; Tan et al., 2011) . Widely distributed in various excitable tissues, including both cardiovascular and nervous systems (Brandt et al., 2003; Mangoni et al., 2003; Nemzou et al., 2006; Striessnig, 2007) , Ca V 1.3 is also involved in a wide spectrum of pathology, including multiple inheritable diseases (Pinggera and Striessnig, 2016; Platzer et al., 2000) . As one prominent exemplar of its pathophysiological linkage, Ca V 1.3 expressed in substantia nigra pars compacta (SNc) neurons tightly controls the autonomous subthreshold Ca 2+ oscillations which have been considered to underlie the pathophysiology of Parkinson's disease (PD) (Chan et al., 2007; Guzman et al., 2009 Guzman et al., , 2010 . Ca V 1.3 is tuned by its own distal carboxyl tail (DCT) to compete with apoCaM (Ca 2+ -free calmodulin), which is pre-associated with the carboxyl terminus of the channel at preIQ 3 -IQ domain (denoted as IQ V ). Closely involved in both apoCaM and Ca 2+ /CaM binding (Jurado et al., 1999) , IQ V plays important roles in channel functions Liu et al., 2010; Singh et al., 2006; Wahl-Schott et al., 2006) . The competitive tuning is highly regulated by fluctuations of [apoCaM] , the strength of particular DCT isoforms, or the apoCaM affinity with IQ V (Adams et al., 2014; Bazzazi et al., 2013; Liu et al., 2010) . DCT consists of two putative a-helical domains-a proximal and a distal C-terminal regulatory domain (termed PCRD and DCRD, respectively) (Hulme et al., 2006) . Positively charged PCRD could coordinate with negatively charged DCRD, in the context of Ca V 1.3 (Liu et al., 2010) , to regulate effective CaM affinity to the IQ V region of the channel. Besides the reported inhibition on Ca 2+ -dependent inactivation (CDI) (Liu et al., 2010; Singh et al., 2006; Wahl-Schott et al., 2006) , several studies suggest that DCT also concurrently attenuates voltage-gated activation (VGA), reducing the maximum open probability and positively shifting the voltage dependence (Hulme et al., 2006; Lieb et al., 2014; Liu et al., 2016; Scharinger et al., 2015; Singh et al., 2008; Wahl-Schott et al., 2006) . Altogether, this competitive tuning of Ca V 1 gating (activation/inactivation) emerges as a new modality distinct from conventional inhibitions such as intensively-studied Ca 2+ channel blockers (CCBs) that normally only reduce VGA (Hockerman et al., 1997) , or Ca 2+ /CaM-triggered conformational changes that induce CDI (Ben- . However, several key matters still remain to be clarified before such new CMI (C-terminus Mediated Inhibition) could be fully established. First, PCRD, DCRD and IQ V seemingly work cooperatively to mediate CMI as suggested by aforementioned analyses, but the exact interrelationships among these three motifs are yet to be elucidated. Second, CMI is supposed to act on channels in an acute manner similar to widely-applied CCBs or like interventions, but direct evidence is still lacking. Third, CMI is expected to reduce the overall Ca 2+ influx; however, it is still unclear whether and how CMI is able to ensure the actual inhibition when both VGA and CDI are attenuated, apparently leading to contradictory effects on Ca 2+ influx.
Embarking on these frontiers regarding CMI, we unveiled the principle of cooperation among the three key C-terminal motifs, with which we developed chemical-inducible CMI for Ca V 1.3 channels. We then resolved all the aforementioned questions crucial to establish CMI, and gained new insights eLife digest All cells need calcium ions to stay healthy, but having too many calcium ions can interfere with important processes in the cell and cause severe problems. Proteins known as calcium channels on the cell surface allow calcium ions to flow into the cell from the surrounding environment. Cells carefully control the opening and closing of these channels to prevent too many calcium ions entering the cell at once. Ca V 1.3 channels are a type of calcium channel that are important for the heart and brain to work properly. Defects in Ca V 1.3 channels can lead to irregular heart rhythms and neurodegenerative diseases such as Parkinson's disease.
Studies have shown that part of the Ca V 1.3 channel that sits inside the cell -known as the "tail" -responds to increases in the levels of calcium ions inside the cell by closing the channel. The tail region of Ca V 1.3 contains three modules, but how these modules work together to regulate channel activity is not clear. Liu, Yang et al. investigated whether the three modules need to be physically connected to each other in the channel protein. For the experiments, several versions of the protein were constructed with different combinations of tail modules being directly linked as part of the same molecule or present as separate molecules. When any two modules were directly linked, the third module could bind to them and this was enough to close the Ca V 1.3 channel. However, the channel did not close if the modules were totally isolated from each other as three separate molecules.
Certain types of neurons in the brain produce electrical signals in a rhythmic fashion that depends on Ca V 1.3 channels. In Parkinson's disease, increased movement of calcium ions into these neurons via Ca V 1.3 channels interferes with the rhythms of the signals and can cause these cells to die. Liu, Yang et al. performed computer simulations to analyse the effects of closing Ca V 1.3 channels in these neurons. The results suggest that this can restore normal rhythms of electrical activity and prevent these cells from dying.
The next step is to understand the molecular details of how the tail region closes Ca V 1.3 channels and its role in healthy and diseased cells. This may lead to new ways to block Ca V 1.3 channels in different types of diseases.
into Ca V 1.3 gating by comparing CMI and CDI. In addition, with computational modeling of Ca 2+ oscillations and pacemaking behaviors under the control of Ca V 1.3 channels in SNc neurons, we explored the potentials of CMI-based inhibitors as therapeutic interventions for Ca V 1.3-related PD.
Results
Provisional CMI concurrently attenuates both CDI and VGA Alternative splicing at the carboxyl terminus of a 1D results into two important native variants of long and short forms: a 1DL (exon 42) and a 1DS (exon 42A). Short variant of a 1DS terminates shortly after the IQ V motif and lacks almost entire DCT domain, and its Ca 2+ current (I Ca ) exhibited strong CDI and VGA ( Figure 1A) . Regarding CDI, a 1DS still contains all the core elements including the IQ V domain for apoCaM pre-association and the EF-hand motifs and N-terminal Ca 2+ /CaM binding NSCaTE motif for CDI transduction. I Ca upon depolarization rapidly decayed (second row, red trace), indicative of strong CDI. In contrast, Ba 2+ current (I Ba ) decayed rather slowly (trace in grey) representing the background voltage-dependent inactivation (VDI). Thus, the fraction of peak current (I peak ) remaining after depolarization for 50 ms (third row, r 50 ) is closely correlated with inactivation, with the difference between the r 50 profiles in Ba 2+ and Ca 2+ serving as the ideal index of CDI. In practice, due to rather weak VDI of Ca V 1.3 at 50 ms (r 50,Ba close to 1) (Tadross et al., 2010) , thus for simplicity the value of 1Àr 50,Ca at À10 mV was taken as the index of CDI strength (S Ca ). VGA was evaluated by peak current density J peak (pA/pF), measured at different voltages while excluding potential artifacts due to cell-size factor (capacitance). Throughout this study, S Ca and J Ca (J peak at À10 mV) served as the quantitative indices for CDI and VGA respectively. Thus, by way of DCT competition against apoCaM, the provisional CMI was expected to attenuate both S Ca and J Ca , as suggested by prior studies (Liu et al., 2010; Singh et al., 2008 Singh et al., , 2006 Tan et al., 2011 Tan et al., , 2012 Wahl-Schott et al., 2006) . However, most of these reports focused on either CDI or VGA only; or even when both were studied for whole-cell I Ca , CDI and VGA were separately evaluated with different experimental groups. Here, we conducted a side-by-side analysis for each variant or condition, not only more confirmative since concurrent changes in CDI and VGA would be mutually supportive, but also critical to later insights into CMI mechanisms and significance originated from such concurrency. Technically, compared to VGA and J Ca , CDI and S Ca are more robust so more favorable since CDI of Ca V 1.3 is independent of global Ca 2+ so insensitive to Ca 2+ -buffer capacities and variations in channel expressions partly due to transient transfections Tadross et al., 2008) . In general, for data and analyses we provided for both CDI and VGA, CDI (S Ca ) was considered as the major index for CMI evaluations and VGA as the supplement.
To establish CMI, several key issues as introduced earlier regarding its mechanisms of action and potential applications need to be clarified. We decided to employ homologous DCT F from Ca V 1.4 (a 1F ) with the strongest DCT tuning effects (stronger than DCT D ) among the Ca V 1 members (Figure 1-figure supplement 1) , to construct the channel variant by fusing PCRD F -DCRD F onto a 1DS right after IQ V motif; meanwhile, since the potency of DCT effects is mainly determined by DCRD (Liu et al., 2010) , PCRD from either Ca V 1.3 or Ca V 1.4 supposedly makes no or little difference and thus we did not distinguish these two PCRD isoforms in this work. Such channel variant was simply denoted as a 1DS -PCRD-DCRD, which represents CMI intrinsic to the long variant of Ca V 1.3 (a 1DL ) but with higher potency since strong DCRD F replaces endogenous DCRD D . Compared with a 1DS control, S Ca and J Ca from a 1DS -PCRD-DCRD were substantially attenuated, which provided ample dynamic ranges (highlighted by green areas) to explore CMI effects on CDI/VGA and its mechanisms ( Figure 1B ).
Differential roles of DCRD and PCRD unveiled by low [apoCaM]
With such baseline CMI effects of PCRD-DCRD, we went further to examine whether both PCRD and DCRD are required, by fusing only PCRD or DCRD onto a 1DS . Since DCRD might need some structural freedom as in DCT or PCRD-DCRD, a glycine linker of different length (G X ) was inserted between DCRD and IQ V to construct a 1DS -G X -DCRD, mimicking the configurations that permit potent effects. From all these channel variants, we concluded no alteration in CDI in comparison with the a 1DS control, similarly from VGA results and analyses ( Figure 2A and . In general, current densities should be more carefully scrutinized before any conclusive claim on VGA; and effects on J peak profiles and J Ca values normally need to be backed up by evaluations on concurrent CDI. For instance, current densities of a 1DS -G X -DCRD (Figure 2 -figure supplement 1A, the three columns on right) seemed different from the control, potentially interpreted as mild CMI; however, considering that the changes in CDI of these channels were rather small, the mild changes in VGA should be considered as variations instead of conclusive attenuations. Statistical test of significance (Student's t-test) was performed subsequently to help identify significant CMI effects. Based on the fact that all the configurations under test failed to mediate S Ca and J Ca attenuations, all the three motifs of PCRD, DCRD and IQ V might be required for effective CMI, consistent with the preliminary analyses on DCT subsegments from Ca V 1.3 and Ca V 1.4, in which the segment between PCRD and DCRD ('B' region) was dispensable but neither PCRD nor DCRD could be excluded (Liu et al., 2010) . Notably, these channel variants expressed in HEK cells were quantified under normal concentrations of Ca 2+ -free CaM ([apoCaM]), in which the three-motif complex of IQ V /PCRD/DCRD as the core of CMI was perturbed by apoCaM that tends to pre-associate with IQ V of the channel. To alleviate the interference with the potential cooperation in forming the threesome complex, we managed to substantially reduce [apoCaM] in the cells by overexpressing BSCaM IQ , a strong apoCaM buffer (Black et al., 2006) , to help identify the minimum requirement for CMI ( Figure 2B ). In contrast to strong CDI in normal [apoCaM] evidenced from different channel variants ( Figure 2A) , with [apoCaM] being substantially reduced (but not lower than a realistic limit), surprisingly, a 1DS -G 24 -DCRD and all the other DCRD-containing variants exhibited much attenuated CDI indicative of effective CMI ( Figure 2C ,D and Figure 2 -figure supplement 1). Meanwhile, the stereotyped ultrastrong CDI normally observed from a 1DS or a 1DS -PCRD was nearly unaltered by apoCaM buffers, in that under the residue [apoCaM] these channels were still able to be pre-bound with apoCaM considering the effective affinity between apoCaM and the channel (IQ V or IQ V -PCRD) was reasonably high when there was no interference. Hence, mechanistically only DCRD and IQ V are required by CMI so that PCRD becomes dispensable if [apoCaM] is low, unveiling the differential roles of PCRD and DCRD in the potential cooperation for CMI induction.
Cooperative scheme of CMI consists of three major combinations
The data thus far suggest that CMI mainly relies on DCRD/IQ V binding to overcome free [apoCaM] of substantial level in normal cell conditions; and PCRD could facilitate CMI potentially by enhancing the binding of DCRD/IQ V and thus the competition against apoCaM. However, the trio failed to attenuate CDI when they were separately expressed as three individual peptides ( Figure 3A-C) , even when PCRD, DCRD and IQ V (contained in a 1DS ) were all well expressed in the same cell as confirmed with fluorescent tags (Figure 3-figure supplement 1) . By examining VGA (J Ca ) with aforementioned precautions, we also concluded that no CMI effect on a 1DS was detectable with all the three groups of peptides: PCRD and DCRD, PCRD only, and DCRD only. When [apoCaM] was reduced with chelator BSCaM IQ as in Figure 2 , CDI remained ultrastrong and indistinguishable from a 1DS control for all the three test groups ( Figure 3D-F) , and VGA analyses came to the same conclusions consistently (Figure 3 -figure supplement 2D-F). Up to here, we established two extreme cases for CMI, i.e., either all the three motifs were fused together (strong CMI), or the three were totally isolated to each other (no CMI). To explore intermediate conditions between the two extremes, we physically linked every two modules out of the three to coexpress with the third one, yielding three possible combinations in total. And they were, PCRD-DCRD peptides to coexpress with IQ V (contained in a 1DS ) ( Figure 4A , combination I), channels containing IQ V -PCRD to coexpress with DCRD ( Figure 4B , combination II), and channels containing linked IQ V and DCRD to coexpress with PCRD ( Figure 4C , combination III). Interestingly, all the three combinations exhibited CMI, strongly attenuating both CDI and VGA as illustrated by green areas indicating the altered r 50 and J peak profiles compared to a 1DS control ( Figure 4A -C). Combination I also provided a great chance to revisit the assumption we made earlier regarding interchangeable PCRD D and PCRD F from Ca V 1.3 and Ca V 1.4, respectively. Instead of dealing with two different channel variants, here the same a 1DS served as the control to reliably evaluate PCRD D -DCRD vs PCRD F -DCRD peptides. And our assumption was validated by the negligible differences in VGA and CDI between the two PCRD-DCRD peptides (Figure 4-figure supplement 1). In previous reports, combinations of I and II were already suggested when studying endogenous DCT in Ca V 1.3 (a 1DL ) and Ca V 1.4 (Singh et al., 2008 (Singh et al., , 2006 . In addition, PCRD (combination III) was able to induce pronounced CMI effects as we first observed in this work, which also completed all the three possible combinations of peptide-mediated CMI.
Live-cell FRET two-hybrid assays demonstrated that DCRD bound IQ V -PCRD with higher affinity ( (Liu et al., 2010) . Both this putative PCRD/DCRD interaction and the binding between IQ V and DCRD should be weaker and secondary compared to the strong binding between IQ V -PCRD and DCRD ( Figure 4D ). This explained why the potential contributions of these secondary interactions may or may not be evidenced, depending on whether the trio complex would come into being in particular settings. Our FRET binding analyses are consistent with the functional data shown earlier, thus providing additional information for the collaborations among CMI motifs. For instance, coexpression of all the three but separate components would not produce CMI ( Figure 3A) . Also, DCRD strongly attenuated a 1DS -PCRD but not a 1DS control ( Figure 4B vs Figure 3C ).
Taken together, a cooperative scheme of CMI under physiological [apoCaM] in the cell was unveiled by functional and binding analyses ( Figure 4E ), which depicted that if any two components have enough spatial closeness or intimacy, e.g., by prearranged linkage, it would be sufficient for the third component to form the 'trio' complex and thus induce effective CMI (combinations of I, II and III, highlighted in grey ellipses). Also, the fusion of all the three components together mimics the intrinsic CMI in a 1DL (positive control, Figure 1B) ; and expression of three components separate to each other represents the negative control with no CMI ( Figure 3A) . Acute CMI based on rapamycin-inducible heterodimerization and cooperation Based on such cooperation-dependent CMI ( Figure 4E ) and rapamycin-mediated heterodimerization (Yang et al., , 2007 , we devised the strategy to implement drug-inducible CMI, illustrated in the design of version 1 ( Figure 5A ). FKBP (rapamycin-binding protein) and FRB fragment (FKBP and rapamycin binding domain of the kinase mTOR) as the tags were fused onto DCRD and PCRD, respectively. A small immunosuppressant molecule rapamycin that binds both FRB and FKBP was applied to link one FKBP-DCRD together with one PCRD-FRB, aiming to bind to the IQ V domain of a 1DS to compete off apoCaM and thus induce CMI according to the scheme of combination I ( Figure 4E ). This design, if successful, should be directly applicable to native Ca V 1.3 since no modification is needed at the channel side. Attracted by such potentials, we implemented and validated this rapamycin-inducible peptide-mediated CMI in HEK cells with a 1DS . In contrast to the stable time-course profiles of the control group ( Figure 5B), CDI (S Ca ) and VGA (I peak ) were both rapidly attenuated upon applying 1 mM rapamycin. Within tens of seconds, dimerization between FKBP-DCRD with PCRD-FRB started to attenuate I Ca as evidenced by time-dependent decays ( Figure 5C ).
Encouraged by the first prototype of inducible CMI, we then proceeded to enhance the potency from moderate (as in version 1) to ultrastrong attenuation similarly as in Figure 1B . We reasoned that the underperformance here should be mainly due to the low effective concentration of the linked peptides if closely comparing constitutive ( Figure 4A ) and the rapamycin-inducible CMI ( Figure 5C ). The upgrade version (version 2) was designed to enhance concentration (local to channels) and thus the potency of CMI peptides. Membrane-targeting motif Ras (Yang et al., 2007 ) was used to construct FRB-CFP-Ras, which would bind DCRD/PCRD tagged with FKBP through rapamycin-inducible heterodimerization. As demonstrated by confocal fluorescence imaging, in about two minutes YFP-FKBP-DCRD and YFP-FKBP-DCRD translocated to the membrane upon rapamycin application ( Figure 5D , Figure 5 -figure supplement 1). Meanwhile, FRB was also fused onto the channel to construct a 1DS -G 12 -FRB for inducible dimerization with FKBP-PCRD or FKBP-DCRD, to facilitate peptide-mediated CMI according to the schemes of combination II and III ( Figure 4E , Figure 5D ). More potently than the earlier design but in a similar time course (version 1, Figure 5B , C), rapamycin induced strong CMI effects on I Ca within 4-5 min (version 2, Figure 5E ,F). Both CDI and VGA were substantially attenuated: S Ca (0.41 ± 0.06, n = 5) and I peak (35% ± 3%, n = 5). Both indices reached the plateau within 4-5 min, which was about the speed of full solution exchange in our recording system, indicating that rapamycin perfusion was the major time-limiting factor. Thus, the acute nature of CMI was strongly supported by the temporal profiles of inducible CMI effects on CDI/VGA (both version 1 and version 2).
To further consolidate the results, direct drug-channel effects were examined for rapamycin as the negative controls; and full CDI and VGA profiles were characterized across the whole voltage range before and after applying rapamycin ( Figure 5-figure supplement 2 ).
CMI is a unique type of inhibition but sharing similarities with CDI One interesting feature we discovered from rapamycin-inducible CMI was that the current amplitude at 300 ms (I 300 ) stayed at the same levels during the whole time course ( Figure 6A , top two rows), in contrast to rapidly decayed I peak as outlined by blue dotted lines. In this context, CMI was quite unique compared to other conventional inhibitions. In the run-down process (Kepplinger and Romanin, 2005) or the blockage by isradipine (Anekonda and Quinn, 2011) , the number of functional channels was reduced, which resulted into attenuations on I Ca during the whole depolarization step including both I peak and I 300 ( Figure 6A, lower two rows) . In contrast, S Ca remained constant for a 1DS undergoing run-down or blockage since intrinsic gating properties (e.g., CDI) of each channel were not altered, whereas S Ca was attenuated in CMI ( Figure 6-figure supplement 1A) .
Would such constant I 300 be just a coincidence? By revisiting different channel variants tested earlier, we concluded that I 300 indeed remained at similar amplitudes for them all ( Figure 6B) , whereas their I peak and S Ca exhibited broad dynamic ranges. To confirm, depolarization pulses of longer duration (1000 ms) were also utilized to conduct constitutive and rapamycin-inducible CMI (Figure 6-figure supplement 2) . In both modalities of CMI, the behavior of I 300 was similar to I 1000 and both indices remained constant. In addition, CDI already approached its steady-state at 300 ms (endstage CDI), and the slight difference between I 300 and I 1000 was largely due to VDI and negligible in this study. Throughout this work, I 300 was employed as the major index to for both CMI and CDI analyses.
The constant I 300 (or J 300 ) essentially set the lower limit for CMI. That said, while CMI potency was getting higher, J peak was tuned down to more closely approach J 300 (e.g., Figure 6B vs Figure 1B ). More clear evidence came from rapamycin-inducible CMI: the attenuated I peak and constant I 300 altogether account for S Ca (CDI) attenuation; and for ultrastrong CMI, S Ca would be nearly abolished (0), indicating that I peak would reach approximately the level of its lower limit (I 300 ).
These lines of evidence also led us to conclude that a reduction of Ca 2+ influx is guaranteed for CMI, despite concurrent VGA/CDI (activation/inactivation) attenuations. Such concurrency apparently would cause contradictory effects on Ca 2+ influx: inhibition of CDI (ICDI) would tend to enhance Ca 2+ influx, in opposition to attenuation on VGA (less Ca 2+ influx). Even though, we just clarified that CMI attenuation on CDI is actually realized by reducing I peak while maintaining the endstage I Ca (indexed with I 300 or I 1000 ), which ensures the overall Ca 2+ influx is reduced. Thus, the major uncertainty was relieved for CMI to emerge as a one new modality of Ca 2+ channel inhibition.
These observations are consistent with the speculation that CDI might be the reversed process to the apoCaM promotion of open probability (Adams et al., 2014) . High similarities are shared by DCT/apoCaM-dependent CMI and Ca 2+ /CaM-mediated CDI: functionally CMI (ultrastrong) and CDI (end-stage) could result into similar gating; and mechanistically they appear to be triggered by similar events: the pre-association between apoCaM and IQ V is either totally abolished (CMI) or drastically altered (CDI) ( Figure 6C ). These facts suggest that potentially the same set of 'core machinery' (cyan square) mediates both CMI and CDI with very similar structures and structural changes. To exclude potential complications from ambient Ca 2+ /CaM, we performed FRET experiments to ensure that the interactions within the trio complex of IQ V /PCRD/DCRD were largely unaffected by Ca 2+ /CaM produced from ionomycin-introduced Ca 2+ and endogenous CaM, although Ca 2+ /CaM indeed exhibited higher binding affinity to IQ V than apoCaM ( Figure 6-figure supplement 3 ).
CMI inhibits Ca V 1.3-mediated oscillation and pacemaking in SNc neurons
Ca V 1.3 plays a pivotal role in subthreshold oscillation and suprathreshold pacemaking in diverse cell types including neurons (Chay and Keizer, 1983; Comunanza et al., 2010) , e.g., dopaminergic neurons in the substantia nigra compacta (SNc) (Chan et al., 2007) . Pathophysiological linkages of PD or other neurodegenerative diseases with Ca V 1.3 functions have been evidenced in multiple lines of studies (Guzman et al., 2009; Puopolo et al., 2007) , including Ca V 1.3 antagonists as potential therapeutic interventions (Anekonda and Quinn, 2011; Pasternak et al., 2012; Triggle, 2007) . To explore the physiological tuning of CMI and its therapeutic potentials, we constructed a customized model for SNc neuron and Ca V 1.3 channels using the software Neuron (Carnevale and Hines, 2006) . Computational analyses were performed to compare the effects between different levels of CMI attenuations, to simulate the tuning of CMI by multiple factors including endogenous DCTs and alternative splicing, apoCaM fluctuations, and apoCaM buffer proteins such as calpacitin (Gerendasy, 1999; Xia and Storm, 2005 Figure 7A -C, left) (green areas indicating the reduction of Ca 2+ influx).
Meanwhile, the time rates of Ca 2+ oscillation and autonomous spiking in the SNc model were also tuned down to different levels in accordance with I Ca attenuations or CMI potencies ( Figure 7A-C) . Experimentally, CMI was compared with other conventional modalities of channel inhibition, for their differences in I Ca attenuations ( Figure 6A , Figure 6 -figure supplement 1). In parallel, we also simulated the conventional blockage in the Ca V 1.3/SNc model ( Figure 7D ). Similar attenuations in oscillation and pacemaking were observed from the SNc model when the moderate (28%) blockade clearly reduced overall Ca 2+ influx (green area), supporting the current strategy to develop PD therapeutics based on conventional Ca V 1.3 antagonists (Gudala et al., 2015; Hurley et al., 2013; Kang et al., 2012; Pasternak et al., 2012) . Collectively, one common rule was deduced for CMI, CDI and other modalities of inhibition: Ca 2+ influx via Ca V 1.3 serves as the major index to determine the downstream of oscillation/pacemaking, i.e., reduction of Ca 2+ influx leads to attenuation of pacemaking whereas enhancement of Ca 2+ influx causes augmentation of pacemaking. These analyses on the potential roles of CMI together with those on CMI mechanisms ( Figure 6C ) suggest that multiple molecular processes in CMI, especially those pertaining to apoCaM and the trio complex, are crucial for excitability and signaling of SNc neurons as well as related pathology, such as PD (Hurley et al., 2013; Scharinger et al., 2015) ( Figure 7E ). In this context, CMI, emerging as one key regulatory mechanism distinct from others, essentially reduces Ca 2+ influx, local and cytosolic Ca 2+ concentration, and oscillation and pacemaking, all of which are potentially subject to bidirectional tuning under pathophysiological conditions.
Discussion
This study focuses on the principle of CMI mediated by multiple carboxyl-tail motifs to compete apoCaM off the channel. Such cooperative competition is applied to rapamycin-inducible inhibition on Ca V 1.3 channels, unveiling that the channel inhibited by ultrastrong CMI should be functionally equivalent to the channel in end-stage CDI. Furthermore, by acute and cooperative inhibition of Ca 2+ influx, this unique CMI serves as potential therapeutic interventions, as demonstrated by attenuation of Ca V 1.3-dependent pacemaking with a computational model of SNc neurons.
CMI across LTCC family and potential physiological linkages
For LTCCs, gating inhibition by carboxyl-tail motifs (CMI) seems to be a universal mechanism preventing excessive Ca 2+ influx and intracellular Ca 2+ overload. In Ca V 1.1 and Ca V 1.2 channels, C-termini of a 1 subunits are subject to proteolytic cleavage and the site of cleavage is located between PCRD and DCRD (Abele and Yang, 2012; Hulme et al., 2005 Hulme et al., , 2006 . Hence, CMI serves as the potential mechanism for endogenous DCRD-containing fragments to attenuate I Ca by cooperating with PCRD and IQ V . For Ca V 1.3, the possibility of proteolytic cleavage has not yet been fully explored. Instead, DCT is subject to alternative splicing thus generating a 1D isoforms in two major categories: with (a 1DL ) or without (a 1DS or similar variants) autonomous CMI (Bock et al., 2011; Singh et al., 2008) , both broadly expressed in various tissues and organs. Ca V 1.4 channels have profound CMI due to its strong DCT against apoCaM, as evidenced by weak inactivation and small currents in native cells, altogether allowing sustained Ca 2+ influx and continuous neural transmission in retinal neurons (Singh et al., 2006 ) and immune cells (Omilusik et al., 2011) . To this end, CMI is a prevalent modality of inhibition across Ca V 1 family members, awaiting further investigations into the molecular mechanisms and pathophysiology.
Mechanistic insights into Ca V 1 gating enlightened by CMI Based on constitutive and inducible CMI effects, we have gained considerable insights into Ca V 1 gating. First of all, CMI as an emerging modality of channel inhibition resembles CDI, one of the prominent features of Ca 2+ channels (Ben- . Targeting the mechanisms of CDI, most structural efforts have been directed to channels in Ca 2+ conditions, evidenced by multiple studies focusing on Ca 2+ /CaM bound with key channel motifs such as IQ or IQ V Fallon et al., 2005; Kim et al., 2008; Mori et al., 2008) and NSCaTE , which have not achieved unequivocal viewpoints toward CDI mechanisms. CMI emphasizes on the importance of apoCaM-bound and apoCaM-off structures in Ca 2+ -free conditions, which represent the states of 'Activated' (pre-CMI) and 'Inhibited' (post-CMI), promisingly holding the key to understand the core mechanisms that control the gating of Ca 2+ channels. Functionally, CMI helps clarify the long-standing complication on the overall effects of CDI on the actual Ca 2+ influx into the cell.
Historically, CDI is considered as a negative feedback to autonomously reduce Ca 2+ entries (Alseikhan et al., 2002; Budde et al., 2002; Liu et al., 2010) . On the other hand, stronger CDI is often accompanied with larger amplitude or facilitated activation of I Ca (Adams et al., 2014; Liu et al., 2016; Singh et al., 2008) , altogether raising the question whether Ca 2+ influx is reduced or enhanced by CDI. Here we provide direct evidence that attenuation of CDI via endogenous factors and mechanisms is essentially a reduction of Ca 2+ influx, assured by the fixed level of Ca 2+ current at the late phase of I Ca , i.e., I 300 measured in this work, remaining the same regardless of the changes in I peak or S Ca . In this context, CMI (in inverse correlation to CDI strength) is the more direct index of channel inhibition. In contrast, CDI strength itself (S Ca ) could be changed by various mechanisms of action besides [apoCaM] tuning, which may or may not actually reduce Ca 2+ influx. For instance, channel mutations in congenital diseases, e.g., Timothy syndrome (Splawski et al., 2004) , could cause less inactivation in I Ca and thus elevate the Ca 2+ entries. Also, small-molecule compounds could produce confounding effects on Ca 2+ influx by triggering multiple events opposed to Figure 6 continued down process and isradipine blockage (bottom two rows), both I peak and I 300 exhibited the declining trends indicating substantial inhibitions. (B) Ca 2+ current density at 300 ms (J 300,Ca ) remained at the same level (indicated by the J 300 values at À10 mV), for various channel variants under test, regardless of whether CMI was in effect. Thick lines (semitransparent in red) represent the J 300,Ca profile of a 1DS control. (C) Functional and the structural insights into the two modes of inhibition. DCT/apoCaM-dependent CMI and Ca 2+ /CaM-mediated CDI result in indistinguishable gating (green arrows) appearing due to similar causes, i.e., either total or partial loss of the apo-state CaM/IQ V complex. That says, in CMI, apoCaM preassociation is totally lost; and in CDI, apoCaM is calcified and dislocated from the pre-association sites. Although the triggers are different for CMI vs CDI, i.e., DCT competing (off apoCaM) vs Ca 2+ binding (onto apoCaM), the similarities between the two different inhibitory regulations of CMI and CDI invite the hypothesis that the core gating machinery (cyan squares) upon depolarization might step into the same scenario/mode including structural details (red arrows). A series of current traces (on the right) indicate CMI with different potency (enhanced from pink to cyan, upper), in comparison with the trace at different stages of CDI (developed from pink to cyan, lower) superimposed with the trace from ultrastrong CMI (dotted trace in cyan). These analyses point to one important notion that the lower limit of CMI is determined by end-stage CDI (the traces or the phases in cyan), and thus the dynamic changes for CMI effects on a 1DS (indexed with I peak and S Ca ) are preset, i.e., from the pink (no CMI and ultrastrong CDI) to the cyan (ultrastrong CMI and no CDI). DOI: 10.7554/eLife.21989.016
The following figure supplements are available for figure 6: each other (Hille, 2001) , e.g., roscovintine (Yarotskyy et al., 2010) reportedly damps activation and meanwhile enhances inactivation, raising uncertainties in its actual effects on Ca 2+ influx.
Therapeutic potentials of CMI-based interventions for PD and beyond
Ca V 1.3 acts as the dominant factor underlying subthreshold oscillation and pacemaking activities in SNc dopaminergic neurons, although the detailed mechanisms are not fully elucidated (Chan et al., 2007; Durante et al., 2004; Putzier et al., 2009) . It is currently believed that activity-dependent engagement of Ca V 1 channels elevates mitochondrial oxidant stress and vulnerability of SNc neurons, contributing to disease progression of PD (Guzman et al., 2010) . Additional support also comes from clinical evidence that Ca V 1 blockers for hypertension treatment, e.g., 1,4-dihydropyridines (DHPs) appear to reduce the risk of PD (Pasternak et al., 2012; Ritz et al., 2009) . However, concerns are raised on developing PD therapeutics based on DHP or like inhibitors. First of all, it has been argued whether Ca V 1.3 is indeed a prerequisite for pacemaking and autonomous oscillation, because of pharmacological complications of DHP, including non-specific side effects and discrepancies in dose dependence (Guzman et al., 2009; Putzier et al., 2009 ). Viral or transgenic delivery of CMI peptides to Ca V 1.3 channels in neurons could circumvent above problems, in hope to unequivocally confirm the actual role of Ca V 1.3. Secondly, PD interventions deploying Ca V 1.3 antagonists could be improved in the following aspects: (1) specificity, for which genetically-encoded CMI-based inhibitors provide the desired specificity intrinsic to Ca V 1 channels; (2) assurance of Ca 2+ reduction, for which CMI is mechanistically guaranteed to reduce Ca 2+ influx; however, certain antagonists may not be able to provide such assurance due to aforementioned reasons. CMI-based interventions and therapeutics could be beneficial to other diseases in addition to PD. A wide spectrum of mental disorders are closely involved in dysregulations of Ca V 1 channels, in that disease-linked mutations in a 1 and b 2 subunits result into abnormal gating properties (Azizan et al., 2013; Cross-Disorder Group of the Psychiatric Genomics Consortium, 2013; Schizophrenia Working Group of the Psychiatric Genomics Consortium, 2014; Scholl et al., 2013) . Encouraged by the results from SNc modeling that the dysregulated Ca V 1.3, Ca 2+ influx and pacemaking could be corrected back to normal, we expect CMI and its therapeutic potentials to manifest in diverse pathophysiology including Ca V 1 channelopathies.
Historical context and future directions
DCT and DCRD effects have been suggested in a few prior works, e.g., DCT peptides truncated from long variants of Ca V 1.3 or Ca V 1.4 to coexpress with the truncated channels lacking the DCT motif (Singh et al., 2008 (Singh et al., , 2006 , mainly to demonstrate the ICDI (inhibition of CDI) effect. Here, to advance the understanding, we clarify that multiple C-terminal motifs cooperatively and acutely compete apoCaM off the channel; and unveil that CMI functionally resembles CDI such that the maximum potency of CMI is preset by end-stage CDI, which also ensures CMI reduces the overall Ca 2+ influx. Moreover, as one major goal beyond basic biophysics, we achieve CMI-based peptides for Ca V 1.3 of native forms, including the short splice variant a 1DS in this work and potentially also the long variant a 1DL , another major isoform in native tissues (Yang et al., 2015) . In parallel, one study focusing on CaM, the other side of the competition, speculated on CDI mechanisms as a simple CaM-off process based on the data produced with local enrichment of apoCaM (Adams et al., 2014) , which, in our view, may have the follow concerns. First, prescreening is needed to control the baseline gating since CaM itself is very well expressed in cells and easily reaches concentrations high enough to diminish the dynamic space to gauge any further change in CDI (Liu et al., 2010) . Second, even with above practical issues being handled, any claims about CDI still await further proof with direct evidence based on actual inhibition such as CMI. Third, apoCaM, due to its central position and multifaceted roles in cell signaling (Cheung, 1980; Chin and Means, 2000; Guzman et al., 2010; Hoeflich and Ikura, 2002) , is nearly impossible to develop into molecular tools and therapeutics. To expand CMI-based inhibitors onto in vivo applications, the approach of rapamycin-mediated heterodimerization may not be directly applicable due to potential interferences with normal cell proliferation, growth and survival (MacMillan, 2013) . Nevertheless, the proof-of-concept prototypes in this work lay the foundations for further development and optimization, e.g., by way of lightinducible dimerization (Kennedy et al., 2010; Levskaya et al., 2009; Yazawa et al., 2009) , to explore the biological ramifications and therapeutic potentials of CMI in diverse settings.
Materials and methods

Molecular biology
a 1D_Short (denoted as a 1DS ) variants were constructed by introducing a unique XbaI site following the IQ domain. PCRD was cloned from either Ca V 1.4 a 1F (NP005174, GenBank accession number, the same as follows) or Ca V 1.3 a 1D (NM_000720); and DCRD was based on Ca V 1.4 a 1F (NP005174), and CFP/YFP-tagged DCRD constructs were made using a similar process as described previously (Liu et al., 2010) . Then other CFP/YFP-tagged constructs were cloned by replacing DCRD with appropriate PCR amplified segments, via unique NotI and XbaI sites, including YFP-PCRD, CFP-PCRD-DCRD, and CFP-CaM. Peptides of IQ V and IQ V -PCRD were cloned from Ca V 1.2 a 1C (NM_199460.3) and Ca V 1.3 a 1D (NM_000720), based on preIQ 3 -IQ and preIQ 3 -IQ-PCRD as the templates respectively. YFP-IQ V and YFP-IQ V -PCRD were cloned similarly as YFP-PCRD. Segments of PCRD-DCRD, PCRD, DCRD with different glycines (G 0 , G 6 and G 24 ) were PCR-amplified with SpeI and XbaI sites and inserted into aforementioned a 1DS .BSCaM IQ , serving as the apoCaM buffer in this study, was kindly provided by Dr. A. Persechini (Black et al., 2006) . Rapamycin-inducible system consisted of FRB, which was based on 93 a.a. rapamycin binding motif of MTOR; and FKBP, which was 108 a.a. human FKBP-12 (AAA58472). Constructs of CFP-PCRD-FRB, YFP-FKBP-DCRD, YFP-FKBP-PCRD and FRB-CFP-ras were made by appropriate design. PCRD segment was amplified by PCR with flanking NotI and EcoRI then cloned directionally via these two unique sites into CFPFRB_pcDNA4_HisMaxC expressing plasmids. DCRD segment was amplified by PCR with flanking BamHI and EcoRI then cloned directionally via these two unique sites into YFP-FKBP_pcDNA4_His-MaxC expressing plasmids. The fusion of YFP-FKBP-PCRD and FRB-CFP-ras were ligated by overlap extension PCR with flanking KpnI and XbaI then cloned into pcDNA3 expressing plasmids via these two unique sites. To make constructs of PCRD-FRB and FKBP-DCRD, segments from CFP-PCRD-FRB and YFP-FKBP-DCRD respectively were amplified by PCR with flanking KpnI and XbaI then cloned directionally into pcDNA4 vector. For chimeric channel a 1DS -G 12 -FRB, a linker containing 12 glycine residues was fused with FRB by overlap PCR with flanking SpeI and XbaI and cloned into a 1DS containing engineered cloning sites before the stop codon.
Transfection of cDNA constructs
For whole-cell electrophysiology and confocal fluorescence imaging, HEK293 cells were cultured in 60 mm dishes or 35 mm No. 0 glass-bottom dishes, and constructs were transiently transfected according to an established calcium phosphate protocol (Liu et al., 2010) . HEK293 cell line was generously provided by Dr. Zhijie Chang (Tsinghua University). The cell line was free of mycoplasma contamination, checked by PCR with primers 5'-GGCGAATGGGTGAGTAACACG À3' and 5'-CGGA TAACGCTTGCGACCTATG À3'. 5 mg of cDNA encoding the desired a 1D subunit, along with 4 mg of rat brain b 2a (M80545) and 4 mg of rat brain a 2 d (NM012919.2) subunits were applied. All of the above cDNA constructs contained a cytomegalovirus promoter. To enhance expression, cDNA for simian virus 40 T antigen (1-2 mg) was also co-transfected with channel constructs. For all the peptides co-transfected, 2 mg of plasmids were added together with channels. Cells were washed with PBS 6-8 hr after transfection and maintained in supplemented DMEM, then incubated for at least 48 hr in a water-saturated 5% CO 2 incubator at 37˚C before electrophysiology experiments and confocal microscopy experiments.
For FRET optical imaging, HEK293 cells cultured on 35 mm No. 0 glass-bottom dishes were transfected with cDNAs (1-5 mg each) by Lipofectamine 2000 (Invitrogen, Waltham, MA). Cells were washed with PBS 4-6 hr after transfection and maintained in supplemented DMEM, then incubated for 24-48 hr in a water-saturated 5% CO 2 incubator at 37˚C before FRET 2-hybrid experiments.
Whole-cell electrophysiology
Whole-cell recordings of transfected HEK293 cells were performed at room temperature (25˚C) using an Axopatch 200B amplifier (Axon Instruments, Sunnyvale, CA). Electrodes were pulled with borosilicate glass capillaries by a programmable puller (P-1000, Sutter Instruments, Novato, CA) and heat-polished by a microforge (MF-830, Narishige, Japan), resulting in 1-3 MW resistances, before series resistance compensation of about 70%. The internal solutions contained (in mM): CsMeSO 3 , 135; CsCl 2 , 5; MgCl 2 , 1; MgATP, 4; HEPES, 5; and EGTA, 5, adjusted to 290 mOsm with glucose and pH 7.3 with CsOH. The extracellular solutions contained (in mM): TEA-MeSO 3 , 140; HEPES, 10; CaCl 2 or BaCl 2 , 10, adjusted to 300 mOsm with glucose and pH 7.3 with TEAOH, all according to the previous reports (Liu et al., 2016 (Liu et al., , 2010 . For run-down experiments, the content of MgATP (Sigma-Aldrich, St. Louis, MO) in the internal solutions was intentionally reduced. Chemical reagents used for blockage experiments (isradipine, Sigma-Aldrich) and drug-inducible experiments (rapamycin, Fisher Scientific, Waltham, MA) were dissolved in DMSO as 10 mM or 1 mM stock solution, stored at À20˚C, and then diluted to 10 mM or 1 mM using extracellular Ca 2+ solution right before experiments. Whole-cell currents were generated from a family of step depolarization (À70 to +50 mV from a holding potential of À70 mV) or a series of repeated step depolarization (À10 mV from a holding potential of À70 mV). Currents were recorded at 2 kHz low-pass filtering of the instrument.
Traces were acquired at a minimum repetition interval of 30 s. P/8 leak subtraction was used throughout.
FRET optical imaging
FRET 2-hybrid imaging experiments were performed with an inverted microscope (Ti-U, Nikon, Japan) with Neo sCMOS camera (Andor Technology, UK). The light source was from the mercury lamp filtered at the appropriate wavelengths for CFP and YFP by the optical filters mounted at the computer-controlled filter wheel (Sutter Instrument) for excitation, subsequently passing the dichroic mirror and the emission filters. Operations and measurements were controlled by the iQ software (Andor Technology). FRET data were acquired and analyzed by an intensity-based twohybrid assay (3 3 -FRET) as described (Butz et al., 2016; Erickson et al., 2001; Liu et al., 2010) ,
where FR max represents the maximum FRET ratio FRpertaining to the receptor (YFP), and D free denotes the equivalent free donor (CFP-tagged) concentration. By fitting the curve of FR À D free with a set of customized Matlab (Mathworks, Natick, MA) codes to iteratively estimate FR max and D free , effective dissociation equilibrium constant (K d ) can be achieved for each binding pair to evaluate the (relative) affinity. During imaging, the bath solution was Tyrode's buffer, containing (in mM): NaCl, 129; KCl, 5; CaCl 2 , 2; MgCl 2 , 1; HEPES, 25; glucose, 30, 300 mOsm, adjusted with glucose and pH 7.3, adjusted with NaOH. Ionomycin (Sigma-Aldrich) was dissolved in DMSO as 1 mM stock solution, stored at À20˚C, and diluted to 1 mM using Tyrode's buffer immediately before applications.
Confocal fluorescence imaging
Fluorescence images were achieved in HEK293 cells transfected with membrane-localized CFPtagged FRB and cytosolic FKBP-PCRD/DCRD tagged with YFP. Dynamic translocations were observed with a ZEISS (Germany) Laser Scanning Confocal Microscope (LSM710) through a 100X oil objective and analyzed with ZEN 2009 Light Edition software and Adobe Photoshop CS5 software (Adobe Systems, San Jose, CA).
